BofA/Merrill Lynch Downgrades Pacira Pharmaceuticals (PCRX) to Neutral Citing Fair Valuation following Rebound
Tweet Send to a Friend
BofA/Merrill Lynch downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Buy to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
